A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

Trial Details

NCT ID
NCT06179160
Phase
PHASE1
Sponsor
Incyte Corporation
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • INCB161734
  • Cetuximab
  • Retifanlimab
  • GEMNabP
  • mFOLFIRINOX
  • FOLFOX
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Palo Alto, California, United States|37.44188,-122.14302
  • Santa Monica, California, United States|34.01949,-118.49138
  • Denver, Colorado, United States|39.73915,-104.9847
  • Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

  • ≥18 years old.
  • Locally advanced or metastatic solid tumor with KRAS G12D mutation.
  • For Part 1a and Part 2 Combination Groups 1, 2, and 7: Disease progression on prior standard treatment, intolerance to or ineligibility for standar…
  • Cohort specific requirements aas defined in the protocol.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →